GTBP
Price:
$3.05
Market Cap:
$6.81M
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies fo...[Read more]
Industry
Biotechnology
IPO Date
2018-03-27
Stock Exchange
NASDAQ
Ticker
GTBP
According to GT Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.39. This represents a change of -45.79% compared to the average of -0.72 of the last 4 quarters.
The mean historical PE Ratio of GT Biopharma, Inc. over the last ten years is -2.55. The current -0.39 PE Ratio has changed 1.43% with respect to the historical average. Over the past ten years (40 quarters), GTBP's PE Ratio was at its highest in in the June 2016 quarter at 41.24. The PE Ratio was at its lowest in in the June 2021 quarter at -801.54.
Average
-2.55
Median
-1.42
Minimum
-15.63
Maximum
3.34
Discovering the peaks and valleys of GT Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 774.84%
Maximum Annual PE Ratio = 3.34
Minimum Annual Increase = -567.31%
Minimum Annual PE Ratio = -15.63
Year | PE Ratio | Change |
---|---|---|
2023 | -1.36 | -1.47% |
2022 | -1.38 | -5.91% |
2021 | -1.46 | 46.35% |
2020 | -1.00 | 774.84% |
2019 | -0.11 | -96.98% |
2018 | -3.78 | -75.81% |
2017 | -15.63 | -567.31% |
2016 | 3.34 | -293.15% |
2015 | -1.73 | -27.30% |
2014 | -2.38 | -97.80% |
The current PE Ratio of GT Biopharma, Inc. (GTBP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.40
5-year avg
-1.06
10-year avg
-2.55
GT Biopharma, Inc.’s PE Ratio is greater than Allarity Therapeutics, Inc. (-1.66), greater than NeuroBo Pharmaceuticals, Inc. (-0.53), less than Hillstream BioPharma, Inc. (-0.00), greater than Virax Biolabs Group Limited (-0.68), greater than Quoin Pharmaceuticals, Ltd. (-0.44), less than Panbela Therapeutics, Inc. (-0.06), less than Virpax Pharmaceuticals, Inc. (-0.08), less than Revelation Biosciences, Inc. (-0.09), less than Biodexa Pharmaceuticals Plc (-0.21), greater than Praxis Precision Medicines, Inc. (-10.65), greater than Pulmatrix, Inc. (-0.70), less than Oncorus, Inc. (-0.04), greater than Akari Therapeutics, Plc (-1.14), greater than Sonnet BioTherapeutics Holdings, Inc. (-2.73), greater than Landos Biopharma, Inc. (-5.74), greater than Cingulate Inc. (-1.18), greater than SAB Biotherapeutics, Inc. (-0.93), greater than Anebulo Pharmaceuticals, Inc. (-5.95), greater than Cadrenal Therapeutics, Inc. Common Stock (-2.44), greater than Monopar Therapeutics Inc. (-8.34), greater than Protara Therapeutics, Inc. (-1.35), less than Vaccinex, Inc. (-0.33), greater than Miromatrix Medical Inc. (-3.41), greater than Surrozen, Inc. (-0.70),
Company | PE Ratio | Market cap |
---|---|---|
-1.66 | $1.99M | |
-0.53 | $21.47M | |
-0.00 | $4.17M | |
-0.68 | $8.86M | |
-0.44 | $2.86M | |
-0.06 | $1.80M | |
-0.08 | $3.47M | |
-0.09 | $3.19M | |
-0.21 | $3.30M | |
-10.65 | $1.24B | |
-0.70 | $7.59M | |
-0.04 | $3.14M | |
-1.14 | $29.50M | |
-2.73 | $2.96M | |
-5.74 | $71.68M | |
-1.18 | $11.86M | |
-0.93 | $37.29M | |
-5.95 | $49.01M | |
-2.44 | $15.24M | |
-8.34 | $87.22M | |
-1.35 | $53.43M | |
-0.33 | $9.06M | |
-3.41 | $92.95M | |
-0.70 | $38.09M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GT Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GT Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is GT Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for GT Biopharma, Inc. (GTBP)?
What is the highest PE Ratio for GT Biopharma, Inc. (GTBP)?
What is the 3-year average PE Ratio for GT Biopharma, Inc. (GTBP)?
What is the 5-year average PE Ratio for GT Biopharma, Inc. (GTBP)?
How does the current PE Ratio for GT Biopharma, Inc. (GTBP) compare to its historical average?